Objective-In the light of the reported inconsistent anti-ischaemic and antianginal effects of transdermal glyceryl trinitrate, its efficacy and influence on the effects of intracoronary glyceryl trinitrate were examined during coronary angioplasty, which provides a model of controlled, reversible ischaemia. Design-Double blind, randomised study of the effect of transdermal and intracoronary glyceryl trinitrate on ischaemia during coronary angioplasty. Patients-40 patients with isolated severe stenosis of the left anterior descending coronary artery. Interventions-Patients were randomised (double blind) to transdermal gylceryl trinitrate (10 mg per day) and placebo, starting four to six hours before angioplasty. After 4 one-minute balloon inflations intracoronary glyceryl trinitrate was injected (0.2 mg) and then 4 further oneminute inflations were performed. Main outcome measures-The time to angina and the time to > 0-2 mV ST shift on surface electrocardiogram (ECG) or intracoronary ECG during the individual inflations. Results-These times did not significantly differ during initial inflations between transdermal glyceryl trinitrate (27 (11), 25 (9), and 19 (9) s, respectively) and placebo (34 (11), 30 (8), and 21 (7) s. After intracoronary glyceryl trinitrate, they were significantly prolonged compared with the initial values, without differences between patients with transdermal glyceryl trinitrate (37 (10), 30 (8), and 23 (8) Balloon inflation during coronary angioplasty commonly produces myocardial ischaemia and angina, and provides a method of producing controlled, reversible ischaemia in humans. The intracoronary, intravenous, or sublingual administration of nitrates is known to reduce these effects.l Transdermal administration of glyceryl trinitrate, which is widely used as antianginal therapy with variable benefits, has not been tested in this setting. We studied the effects of transdermal glyceryl trinitrate on myocardial ischaemia during balloon inflation for coronary angioplasty in a randomised double blind, placebo controlled trial and also the possible influence of transdermal glyceryl trinitrate on the effects of subsequently administered intracoronary glyceryl trinitrate.
Abstract
Objective-In the light of the reported inconsistent anti-ischaemic and antianginal effects of transdermal glyceryl trinitrate, its efficacy and influence on the effects of intracoronary glyceryl trinitrate were examined during coronary angioplasty, which provides a model of controlled, reversible ischaemia. Design-Double blind, randomised study of the effect of transdermal and intracoronary glyceryl trinitrate on ischaemia during coronary angioplasty. Patients-40 patients with isolated severe stenosis of the left anterior descending coronary artery. Interventions-Patients were randomised (double blind) to transdermal gylceryl trinitrate (10 mg per day) and placebo, starting four to six hours before angioplasty. After 4 one-minute balloon inflations intracoronary glyceryl trinitrate was injected (0.2 mg) and then 4 further oneminute inflations were performed. Main outcome measures-The time to angina and the time to > 0-2 mV ST shift on surface electrocardiogram (ECG) or intracoronary ECG during the individual inflations. Results-These times did not significantly differ during initial inflations between transdermal glyceryl trinitrate (27 (11), 25 (9) , and 19 (9) s, respectively) and placebo (34 (11) , 30 (8) , and 21 (7) s. After intracoronary glyceryl trinitrate, they were significantly prolonged compared with the initial values, without differences between patients with transdermal glyceryl trinitrate (37 (10) , 30 (8) , and 23 (8) (fig 1) . Coronary angiography was performed initially, after the fourth balloon inflation, after the last balloon inflation, and as required to assess angiographic results. The angiograms were evaluated by two independent observers to assess the primary success of coronary angioplasty (residual stenosis < 50% of luminal diameter as a mean of at least two perpendicular projections), collateral flow, and coronary spasm. In 20 patients the diameter of a normal segment of the proximal left anterior descending coronary artery could be measured by quantitative coronary angiography to assess the coronary vasodilatory effect of intracoronary glyceryl trinitrate. Surface ECG (leads I, II, III, and V2) and intracoronary ECG6 were recorded before and during the first inflation, during each subsequent inflation and after the last inflation. Mean aortic pressure and mean heart rate were noted before and after each inflation. The following variables were measured for each balloon inflation (1) time to onset of angina from the beginning of inflation (primary variable), (2) time to onset of ST segment shift of > 0 2 mV on the surface ECG, (3) time to onset of ST segment shift of > 0-2 mV on the intracoronary ECG, (4) maximum ST segment shift on the surface ECG, (5) maximum ST segment shift on the intracoronary ECG.
The variables recorded during the second to fourth and the sixth to eighth balloon inflations were considered for analysis. The ischaemic response to the first inflation is highly variable. 7 The deflated balloon catheter, by itself, produces variable obstruction to blood flow when first placed across a severe stenosis and, in the setting of a subtotal stenosis, frequently causes ischaemia even before it is inflated. The fifth inflation was performed two minutes after the administration of intracoronary glyceryl trinitrate. This interval could be insufficient to show the maximal effects of intracoronary glyceryl trinitrate.
All variables between the two groups were compared by the Wilcoxon rank-sum test. For within group comparisons we used the paired t test for changes in coronary artery diameter and the Wilcoxon signed-rank test for the other variables. Values are expressed as mean (SD).
Results Thirty nine of the 40 randomised patients had a successful coronary angioplasty with a reduction of luminal diameter stenosis from 83 (9)% to 14 (8)% in the transdermal glyceryl trinitrate group and from 84 (7)% to 10 (6)% in the placebo group. One patient originally randomised to receive transdermal glyceryl trinitrate was excluded because at angiography it was found that the coronary stenosis was not significant and did not warrant coronary angioplasty. Four patients in the transdermal glyceryl trinitrate group and six in the placebo group needed stent implantation for local dissection after balloon inflation. One patient in each group had delayed acute vessel closure leading to myocardial infarction. There were no deaths. TIME TO ONSET OF ANGINA Three patients in the transdermal glyceryl trinitrate group had neither angina nor significant ST changes on ECG during balloon inflations. One in the placebo group had significant ECG changes but no angina during balloon inflations. The time to onset of angina before intracoronary glyceryl trinitrate administration-that is, the average of the values during the second to fourth balloon inflations-was not significantly different with transdermal glyceryl trinitrate and with placebo (27 (11) and 34 (11) s, respectively). After intracoronary glyceryl trinitrate-that is, during the sixth to eighth balloon inflations, the average time to onset of angina was significantly prolonged within each group (37 (10), and 39 (15) After IC GTN n=16 n=18
Before IC GTN Balloon inflations Figure 5 Aortic pressure (mean (SE)) before (A) and after (B) each balloon inflation. (8) 28 (13) ISCHAEMIC PRECONDITIONING
In both the study groups successive balloon inflations before injection of intracoronary glyceryl trinitrate and after it did not increase tolerance to ischaemia (preconditioning) (tables 2 and 3 and 5-7).
Discussion
Over the years the use of transdermal glyceryl trinitrate as an anti-anginal agent has raised several controversies. The problems of variable drug absorption, need for frequent dosing, and fluctuating plasma drug concentrations were overcome by replacing glyceryl trinitrate ointment with the transdermal patch system.9 The daily continuous use of such IC GTN patches, however, led to the problem of nitrate tolerance which was not eliminated by increasing the glyceryl trinitrate dosage'0 but was reduced by intermittent patch administration." Recent data, however, suggest that rebound ischaemia may result from intermittent administration.'2 Further, the effects of 4A 4B 5A 5B 6A 6B 7A 7B 8A 8B transdermal glyceryl trinitrate on exerciseBalloon inflations induced myocardial ischaemia and on symptomatic anginal attacks seem to be unconnected.
efore (A) and after (B) each balloon inflation.
Though exercise-induced ischaemia improved in several studies, evidence that it reduces the ese variables after each balloon inflation frequency of anginal attacks is not convinc-)ared with the values before inflation. A ing.I1 Our observations in the setting of coroand similar decrease in blood pressure nary angioplasty, a model of controlled seen in both groups after intracoronary reproducible ischaemia, accentuate the contion of glyceryl trinitrate (figs 5 and 6).
troversy surrounding the use of transdermal glyceryl trinitrate in patients with coronary artery disease.
Time (s) to angina during balloon inflation
We found that the application of the trans-(SD)) dermal glyceryl trinitrate patch at a dose of 10 Transdermal GTN Placebo mg per day 4-6 hours before coronary angioinitiflation (n = 16) (n = 19) plasty did not influence either the time to 31 (15) 29 (15) onset of angina nor the magnitude or the time 28 (12) 34 (113) to onset of ischaemic changes on surface or 28 (13) 33 (16) intracoronary ECGs during balloon inflation.
37 (14) 41 (13) On the other hand, the administration of intra-34 (10) 39 (17) h 37 (13) 37 (14) coronary glyceryl trinitrate significantly pro-39 (11) 41 (17) longed the time to onset of angina as well as the time to onset of ischaemic changes on both surface and intracoronary ECGs. These effects 6 Time (s) to 0-2 miVnST segment shift in of intracoronary glyceryl trinitrate were neither augmented nor reduced by prior administraTransdermal GTN Placebo tion of transdermal glyceryl trinitrate. inflation (n = 16) (n = 20)
The beneficial effects of glyceryl trinitrate 28 (13) 30 (10) administered by the intracoronary, intra-1~~24 (10) 31 (9) 26 (9) 29 (9) venous, or sublingual routes during coronary 26 (12) 28 (8) angioplasty has been demonstrated in earlier 29 (8)) 395 (82) studies. 1' Transdermal glyceryl trinitrate h 30 (9) 35 (13) including the system used in our study has 31 (9) 36 ( (5) activation of the sympathetic and aldosterone systems by transdermal glyceryl trinitrate, and (6) the mode by which ischaemia is induced during balloon inflation. The dose of transdermal glyceryl trinitrate used in our study (absorption rate of 10 mg/24 h) has been commonly and effectively used in earlier studies and would be deemed adequate for anti-ischaemic effect. 10-4 The interval of 4-6 hours between application of the glyceryl trinitrate patch and the angioplasty procedure in our study allowed sufficient time for drug action. After transdermal administration plasma concentrations of glyceryl trinitrate peak at 2-4 hours and attain a steady state thereafter.15 Nitrate tolerance is more common and occurs more rapidly with treatments that produce steady plasma drug concentrations. However, such tolerance usually occurs beyond eight hours of initial application of a transdermal glyceryl trinitrate patch. [16] [17] [18] [19] In our study, no significant effect on blood pressure or heart rate was noted after transdermal glyceryl trinitrate administration. After intracoronary glyceryl trinitrate, an insignificant fall in blood pressure was noted. It could be argued that the effectiveness of intracoronary glyceryl trinitrate as opposed to transdermal glyceryl trinitrate was related to this difference. The fact that plasma concentrations were not measured turned out to be a considerable flaw of the study. We cannot exclude the possibility that low plasma concentrations after transdermal application accounted for the lack of effect.
On the other hand, the influence of the catecholamine and renin-aldosterone activity on the effect of transdermal glyceryl trinitrate may be responsible for the observed lack of benefit with transdermal glyceryl trinitrate. An earlier study has shown that in subjects with higher catecholamine and renin-aldosterone activity, transdermal Another plausible explanation could be the mode of ischaemia production during balloon inflation. In exercise-induced ischaemia there is a gradual alteration of the balance between myocardial oxygen demand and supply, whereas the ischaemia that occurs during balloon inflation results from rapid occlusion of the coronary artery. It is possible that the relief of ischaemia that is produced so rapidly requires higher or rapidly rising plasma concentrations of glyceryl trinitrate or a more potent glyceryl trinitrate action. It is known that although transdermal glyceryl trinitrate improves exercise-induced ischaemia, this improvement is not maximal and further improvement occurs when sublingual glyceryl trinitrate is additionally administered." This suboptimal effect of transdermal glyceryl trinitrate may be related to the lower or more slowly rising plasma drug concentrations compared with intravenous or sublingual administration or to a differing ratio of the two active dinitrate metabolites of glyceryl trinitrate (the ratio of 1 2 and 1-3 dinitroglyceryl metabolites varies as a function of the route of administration) and may explain its reduced effect in the setting of coronary angioplasty.9 15'2 Therefore, it is possible that the model of ischaemia induced by balloon inflation during coronary angioplasty is not always comparable to models of exercise-induced ischaemia. Nevertheless, our data suggest that pretreatment of patients with glyceryl trinitrate patches before coronary angioplasty cannot be recommended.
An interesting corollary from our study is the absence of evidence for ischaemic preconditioning during successive balloon inflations. Ischaemic preconditioning is not a established phenomenon in humans and our criteria for control inflations (exclusion of the first and the fifth balloon inflations) and the elimination of patients with pre-existing angiographic collaterals are more rigid than in other studies demonstrating this phenomenon.25 25 Absence of preconditioning under similar conditions has recently been suggested.26
